Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers.

PURPOSE The aim of this study was to develop and evaluate a novel three-layered oral delivery system for insulin in vivo. METHODS The patch system consisted of a mucoadhesive layer, a water insoluble backing layer made of ethylcellulose and an enteric coating made of Eudragit. Drug release studies were performed in media mimicking stomach and intestinal fluids. For in vivo studies patch systems were administered orally to conscious non-diabetic rats. Orally administered insulin in aqueous solution was used as control. After the oral administration of the patch systems a decrease of glucose and increase of insulin blood levels were measured. RESULTS The mucoadhesive layer, exhibiting a diameter of 2.5mm and a weight of 5mg, comprised polycarbophil-cysteine conjugate (49%), bovine insulin (26%), gluthatione (5%) and mannitol (20%). 74.8+/-4.8% of insulin was released from the delivery system over 6h. Six hours after administration of the patch system mean maximum decrease of blood glucose level of 31.6% of the initial value could be observed. Maximum insulin concentration in blood was 11.3+/-6.2ng/ml and was reached 6h after administration. The relative bioavailability of orally administered patch system versus subcutaneous injection was 2.2%. CONCLUSION The results indicate that the patch system provides enhancement of intestinal absorption and thereby offers a promising strategy for peroral peptide delivery.

[1]  A. Bernkop‐Schnürch,et al.  Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[2]  A. Bernkop‐Schnürch,et al.  Polycarbophil-cysteine conjugates as platforms for oral polypeptide delivery systems. , 2000, Journal of pharmaceutical sciences.

[3]  D. Ziedonis,et al.  Developments in pharmacotherapy for tobacco dependence: past, present and future. , 2006, Drug and alcohol review.

[4]  A. Bernkop‐Schnürch,et al.  The Role of Glutathione in the Permeation Enhancing Effect of Thiolated Polymers , 2002, Pharmaceutical Research.

[5]  Claus-Michael Lehr,et al.  An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop , 1991 .

[6]  J. Bai,et al.  Effects of Polyacrylic Polymers on the Degradation of Insulin and Peptide Drugs by Chymotrypsin and Trypsin , 1996, The Journal of pharmacy and pharmacology.

[7]  J. Woodley Enzymatic barriers for GI peptide and protein delivery. , 1994, Critical reviews in therapeutic drug carrier systems.

[8]  A. Bernkop‐Schnürch,et al.  Polymers with Thiol Groups: A New Generation of Mucoadhesive Polymers? , 1999, Pharmaceutical Research.

[9]  T. Skaer Transdermal opioids for cancer pain , 2006, Health and quality of life outcomes.

[10]  P. P. Bhatt,et al.  Evaluation of a mucoadhesive buccal patch for delivery of peptides: in vitro screening of bioadhesion. , 1998, Drug development and industrial pharmacy.

[11]  H. Junginger,et al.  Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro , 1997 .

[12]  A. Bernkop‐Schnürch Thiomers: a new generation of mucoadhesive polymers. , 2005, Advanced drug delivery reviews.

[13]  M. Elmazar,et al.  Promotion of oral insulin absorption in diabetic rabbits using pH-dependent coated capsules containing sodium cholate. , 1997, Pharmaceutica acta Helvetiae.

[14]  R. Burkman The transdermal contraceptive system. , 2004, American journal of obstetrics and gynecology.

[15]  R. Gurny,et al.  Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. , 1995, Journal of pharmaceutical sciences.

[16]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[17]  A. Bernkop‐Schnürch,et al.  Synthesis and characterisation of mucoadhesive thiolated polymers. , 2000, International journal of pharmaceutics.

[18]  N. Shibata,et al.  Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein. , 2002, Biomaterials.

[19]  A. Bernkop‐Schnürch,et al.  Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. , 2005, Journal of pharmaceutical sciences.

[20]  N. Shibata,et al.  Possibility of a patch system as a new oral delivery system. , 2003, International journal of pharmaceutics.

[21]  A. Bernkop‐Schnürch,et al.  Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro. , 2000, Biomaterials.

[22]  P. Caliceti,et al.  Design and In Vivo Evaluation of An Oral Delivery System for Insulin , 2000, Pharmaceutical Research.

[23]  H. Junginger,et al.  Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles , 1996 .

[24]  H. Junginger,et al.  MUCOADHESIVE POLYMERS IN PERORAL PEPTIDE DRUG DELIVERY. I. INFLUENCE OF MUCOADHESIVE EXCIPIENTS ON THE PROTEOLYTIC ACTIVITY OF INTESTINAL ENZYMES , 1996 .

[25]  Y. Kawashima,et al.  Enteral Absorption of Insulin in Rats from Mucoadhesive Chitosan-Coated Liposomes , 1996, Pharmaceutical Research.

[26]  Samir Mitragotri,et al.  Intestinal Patches for Oral Drug Delivery , 2002, Pharmaceutical Research.